Please assess the completion status of the following clinical trial:

Trial Title: Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed presence of thrombocytopenia with platelet count \< 30,000/mm3 at the pre-dose visit.~* History of isolated ITP~* RhD-positive serology.~* Previous treatment and response to first line therapy for ITP~Exclusion Criteria:~* Known clinical picture suggestive of other causes of thrombocytopenia, especially systematic lupus erythematosus,antiphospholipid syndrome, Evans syndrome, immunodeficiency states, lymphoproliferative disorders, liver disease,ingestion of drugs such as quinidine/quinine, heparin and sulfonamides and hereditary thrombocytopenia confirmed by relevant laboratory findings.~* Suspected infection with HIV, Hepatitis C, H. pylori.~* Clinical splenomegaly~* History of abnormal bone marrow examination.~* Ongoing haemorrhage corresponding to a grade 3 or 4 on the WHO bleeding scale.~* Underlying haemolytic condition~* History of splenectomy.~* Subject is pregnant, breast feeding or intends to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients treated with Sym001

Based on this trial design, predict the completion outcome and termination type (if applicable).